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emergency department visits in 1999–2001 by individuals aged
25–64 with primary diagnosis of pneumonia, antibiotic pre-
scription within three-days, chest x-ray on index date, continu-
ous enrollment for 12-months prior, 30-days after index visit.
Exclusion criteria: antibiotic prescription, pneumonia diagnosis,
or hospitalization in prior 30-days; initial therapy with multiple
antibiotics; in prior 12-months residence in a long-term 
care facility or diagnosis of cancer of bronchus or lung, sec-
ondary malignancy, HIV/AIDS, cystic ﬁbrosis, immunity disor-
ders. We considered the following comorbid illnesses: chronic
liver, renal or lung disease; cerebrovascular disease; cardiac
disease; diabetes mellitus; malignancy. RESULTS: A total of
5748 cases met criteria, 13.9% initially seen in the emergency
department. Of these, 16.8% had one comorbidity, 3.5% had
multiple comorbidities. Macrolides were the most common
initial therapy (66.5%), followed by quinolones (17.9%).
Quinolone use more than doubled from 1999 to 2001, from
11.8% to 24.3% in patients without comorbidity, from 12.1%
to 33.8% in patients with comorbidities. Overall, 13.1%
received a change in therapy without subsequent hospitalization,
another 3.0% were hospitalized. Females were more likely to
change therapy than males (15.9% vs. 10.5%, p < 0.0001) but
not more likely to be hospitalized (3.0% for both). Failure rates
were strongly associated with number of comorbidities (p =
0.0004), particularly in rates of subsequent hospitalization:
2.4% for no comorbidities, 4.9% for one comorbidity and 7.5%
for multiple comorbidities. Hospitalization without secondary
outpatient therapy was common: 13.5% for patients without
comorbidity, 24.9% for one comorbidity, 28.6% for multiple
comorbidities. CONCLUSION: While macrolides were the most
common therapy, quinolone usage was substantial and rising
rapidly regardless of comorbidity. Hospitalization for patients 
failing therapy was fairly common even in patients without
comorbidity.
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OBJECTIVE: Infections due to P. aeruginosa are associated with
increased likelihood of death and morbidity. Empiric therapy is
often difﬁcult due to increased resistance noted with this organ-
ism. The purpose of this study was to determine the impact of
inappropriate initial empiric therapy on health outcomes of
patients with P. aeruginosa bacteremia. METHODS: Retrospec-
tive cohort study of hospitalized patients with their ﬁrst episode
of P. aeruginosa bacteremia. Patients were stratiﬁed based on
appropriateness of antipseudomonal therapy. Inappropriate
initial empiric therapy was deﬁned as receipt of antibiotic
therapy to which the isolate displayed in vitro resistance. Data
collected included discharge mortality, new ICU admit, new
requirement for ventilator therapy or hemodialysis, and length
of hospital stay. RESULTS: A total of 87 patients (71%
males/29% females) aged 58 ± 17 years (mean ± SD) were iden-
tiﬁed between January, 2002 to April, 2004. Overall mortality
was 44%. Forty-nine percent of patients’ received inappropriate
antibiotic therapy. ApacheII score were signiﬁcantly higher in
patients that died (p = 0.003). Mortality rates were signiﬁcantly
higher in patients treated with inappropriate empiric therapy
(63%) compared to patients treated appropriately (39%, OR =
2.97, p = 0.024). New requirements for ICU admission,
hemodialysis, or ventilator did not differ between the two
groups. CONCLUSIONS: Inappropriate initial empiric therapy
in patients with P. aeruginosa bacteremia signiﬁcantly increased
mortality rates.
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OBJECTIVES: We sought to evaluate which risk factors may be
implicated in prolonged duration of antibiotic treatment in hos-
pitalized patients with complicated skin and structure infections
(cSSSI). METHODS: We pooled data from two double-blind,
randomized, multinational, clinical trials among patients with
cSSSI. Patients were randomly assigned to receive either tigecy-
cline (initial 100mg dose, followed by 50mg twice daily) or van-
comycin with aztreonam (1g vancomycin plus 2g aztreonam,
twice daily) via IV administration. Treatment termination was
based on physician assessment of resolution of signs and symp-
toms of infection, with formal test of cure (TOC) at least 12-
days later. We used a Cox proportional hazard (CPH) model 
to identify potential clinical risk factors for longer time-to-
treatment termination. RESULTS: Among 1041 patients in the
modiﬁed intent-to-treat (m-ITT) population with complete hos-
pitalization data, deep/extensive cellulitis (59%) was the most
common cSSSI diagnosis, spontaneous infection (51%) was the
typical etiology, and diabetes (22%) was the most common
comorbidity. No signiﬁcant differences were observed in baseline
characteristics. Median treatment duration was eight-days for
each treatment group. The estimated CPH model identiﬁed dia-
betes (p < 0.0001), female sex (p = 0.017), infected ulcer (p =
0.001), and use of concomitant antibiotics (p = 0.002) as inde-
pendent risk factors for signiﬁcantly longer treatment duration.
Adjusting for these risk factors, tigecycline was associated with
a trend toward shorter treatment duration overall (p = 0.072)
and within the diabetes, infected ulcer, and female strata. There
was no difference across the treatment groups in the rate of cure
at the TOC visit (p = 0.197). CONCLUSIONS: Diabetes, female
sex, infected ulcers, and use of concomitant antibiotics emerged
as signiﬁcant risk factors for prolonged treatment duration in
cSSSI. Tigecycline, the ﬁrst in a new antibiotic class, the glycyl-
cyclines, was associated with a trend toward shorter treatment
duration, once the risk factors were adjusted for.
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OBJECTIVE: The objective of this study was to determine the
impact of empiric antifungal therapy on mortality in hospital-
ized, non-neutropenic patients with bloodstream candidemia.
METHODS: Retrospective cohort study to evaluate the effect of
empiric therapy on mortality in patients with bloodstream can-
didemia. Medical and hospitalization history were collected from
the medical charts of patients hospitalized from 2002 to 2004
with their ﬁrst documented episode of candidemia. Patients were
grouped by APACHEII scores and choice of empiric antifungal
therapy (narrow spectrum: ﬂuconazole or itraconazole; broad
spectrum: amphotericin, caspofungin, or voriconazole). Impact
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of empiric antifungal therapy was assessed using univariate tech-
niques and multivariate logistic regression. RESULTS: A total of
81 patients were evaluated in this study. Forty-four percent
received broad spectrum, 46% received narrow spectrum, 
and 10% received no therapy. Overall mortality was 51%.
APACHEII >20 and narrow spectrum empiric therapy were inde-
pendent predictors of mortality (p = 0.011). Mortality rates were
similar in patients with Apache score >20 given broad (85%) or
narrow spectrum (79%) empiric therapy. However, in patients
with lower APACHEII scores (<20), mortality was signiﬁcantly
lower in patients started on broad spectrum (4%) compared to
narrow spectrum (46%). After excluding patients who died
while on therapy, average length of therapy was similar for both
groups (11–12 days). CONCLUSIONS: Patients with can-
didemia with an APACHEII score <20 treated with broad spec-
trum antibiotics had lower mortality rates compared to those
initially treated with narrow spectrum antifungal therapy.
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OBJECTIVE: Neutropenia following cancer chemotherapy is a
major risk factor for invasive fungal infections (IFIs). The high
rates of mortality associated with IFIs warrants the use of empir-
ical antifungal therapy. Conventional amphotericin B (CAB) is
considered to be the standard of care in persistently febrile 
neutropenic patients; however, infusion-related reactions and
nephrotoxicity limit its use. Although liposomal amphotericin B
(LAmB) has demonstrated similar efﬁcacy to CAB and is gener-
ally well tolerated, it is associated with a high acquisition cost.
Voriconazole is a potential alternative for empirical therapy of
IFIs. An algorithm for the management of febrile neutropenia
(FN) was implemented at the University of Michigan Health
System (UMHS). The new algorithm, implemented in January,
2003, recommends voriconazole as the preferred antifungal 
for adult Hematology/Oncology patients with FN, except those
with evidence of hepatic dysfunction or who are receiving gem-
tuzumab. The objective of this study was to determine the ﬁnan-
cial impact of this algorithm. METHODS: Patients on the adult
Hematology/Oncology service who ﬁrst received either LAmB or
voriconazole over a two-year period were identiﬁed retrospec-
tively using the UMHS Data Warehouse. Costs were evaluated
from the perspective of the Health System and compared
between the voriconazole and LAmB groups from ﬁrst the anti-
fungal dose to the time of hospital discharge. RESULTS: Seventy-
eight patients were included in the analysis (42LAmB and 36
voriconazole). Antifungal cost per patient declined from $4278
to $3331 in the voriconazole group. This represented a decrease
of $947 per patient. Laboratory cost per patient increased by
$579. The total cost per patient initiated on voriconazole
decreased by $1502. CONCLUSION: The implementation of an
algorithm incorporating voriconazole as the preferred antifungal
agent for empiric treatment of febrile neutropenia was associated
with decreased spending on antifungal agents, increased labora-
tory costs, and a decrease in total costs.
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OBJECTIVES: Children vaccinated with Prevenar have been
shown to be at reduced risk of meningitis, bacteraemia, pneu-
monia and acute otitis media. Vaccination may also affect risk
in unvaccinated individuals by reducing the circulation of infec-
tious organisms in the community, a phenomenon known as herd
immunity. This analysis examined the economic consequences of
Prevenar vaccination incorporating herd immunity effects.
METHODS: An existing model was adapted to consider herd
immunity effects in Germany. Vaccine coverage of 83% was
assumed and the model estimated the number of pneumococcal
events, deaths and associated costs in vaccinated individuals over
ten years. Efﬁcacy came from a large randomised study in the
US, corrected for age speciﬁc German epidemiology. Changes in
rates of infection with vaccine susceptible organisms have been
found by the Active Bacterial Core Surveillance Network in the
US, where Prevenar has been in use for several years. Costs were
estimated from the perspective of society, including four vaccine
doses, treating pneumococcal disease in hospital and the com-
munity, long term disability resulting from infections and 
social security payments. Future costs were discounted at 5%.
RESULTS: The model estimated that vaccination would avoid
98 cases of meningitis, 376 cases of septicaemia and 19 deaths
in vaccinated individuals. Using the percentage reduction in
disease observed in the USA, the model estimated that a further
3940 deaths would be avoided annually in unvaccinated indi-
viduals, mostly by reducing the incidence of pneumonia in the
elderly. The cost per life year gained was 43,000€ in the vacci-
nated cohort alone, but vaccination was cost saving when herd
immunity effects were incorporated. Findings are sensitive to
disease incidence, long-term costs of meningitis and vaccine cost.
CONCLUSION: The model showed that the beneﬁts of Preve-
nar extend beyond vaccinated individuals. Failing to consider
herd immunity effects may substantially understate the economic
beneﬁts of vaccination.
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OBJECTIVES: Acellular pertussis vaccines make immunization
of adolescents more feasible and may help reduce the burden of
pertussis. Based on recent estimates indicating that infection may
be much more common than previously thought, we updated an
economic evaluation of adolescent pertussis vaccination to assess
programs in this new context. METHODS: A model was previ-
ously developed to estimate the effects of pertussis vaccination
of adolescents (ages 11–18) including herd immunity. Inputs for
the US were taken from literature, government data and cost
databases. Recently published incidence estimates replaced pre-
vious CDC-based ones. Where adequate data were unavailable,
estimates were agreed to by an expert panel (the Global Pertus-
sis Initiative). Health beneﬁts were quantiﬁed as cases, deaths,
and disability avoided, and life years gained. Both direct medical
costs and lost productivity costs were considered. All outcomes
were discounted at 3% per year. Time horizon was ten years.
Extensive uni- and multivariate sensitivity analyses were com-
pleted. RESULTS: Adopting new incidence estimates dramati-
cally improves the value of adolescent vaccination, with cases
avoided exceeding two million over ten years. The economic
results switch from the original cost-effective situation to direct
medical savings of $719 million and societal of $1.2 billion, if
parameters other than incidence are unchanged. Sensitivity
analyses show that the cost per case would need to be < 10% of
